Hematopoietic stem cell transplantation (HSCT) was introduced as treatment for patients with CML in chronic phase (CP) in the late 1970's. 1 Transplantation of bone marrow cells from syngeneic donors after high-dose chemotherapy made successful eradication of the Philadelphia positive clone possible. HSCT gained rapid acceptance. By 1999, CML was the most frequent indication for an allogeneic HSCT worldwide. The introduction of tyrosine kinase inhibitors (TKIs) into clinical practice led to declined transplant rates. Expert guidelines do not recommend HSCT as first-line therapy in CP-CML anymore. 2, 3 Only patients who are resistant to at least one 2nd generation TKI are HSCT candidates. 2 Despite its potential to keep a large number of patients free of the disease for 425 years, early transplant-related mortality is considered too high to justify HSCT as a treatment option.
Only a few studies reported on outcomes of HSCT patients with a suboptimal or failed response to TKI. 4, 5, 6 These studies include a mixed group of high and low-risk patients and cannot be considered as a representative. Data on a large patient cohort are lacking. We were therefore especially interested in outcome of patients with low-risk transplants as defined by the European Society of Blood and Marrow Transplantation (EBMT) risk score 7 and transplanted with standard optimal procedures in the tyrosine kinase era.
The present analysis is based on all consecutive transplants for CP-CML patients and reported to the Chronic Malignancies Working Party MED-A database of the EBMT between 2002 and 2005. This time frame was chosen to have sufficient follow-up time and to select patients who most likely had TKI treatment (imatinib or dasatinib) prior to HSCT. MED-A forms contain basic information only. Still, they are sufficient to calculate the EBMT risk score and to assess survival. The database covers more than 90% of all transplants performed in Europe and covered by the EBMT database during the examined time period. In contrast, exact information on pretransplant treatment, detailed information on remission status or on therapy for relapse is missing.
The analysis was restricted to patients with an HLA-identical sibling donor who was transplanted in first CP after myeloablative conditioning with T-replete bone marrow as stem cell source and an EBMT risk score of 0, 1 or 2. Male patients with female donors and patients with an unrelated transplant and those with an EBMT risk score of 3 or more were excluded.
A total of 193 patients fulfilled the selection criteria for such a low-risk transplant. This corresponds to 6% of all 3057 allogeneic HSCT for CML in Europe during this time period. Patients were 45% males and 55% females with a medium age of 31 years (range 6-59 years). 40 (21%) patients were younger than 20 years old and 41 (21%) were above the age of 40 years. The time interval from diagnosis to transplant was o 12 months in 165 patients (86%). About 19% of patients had an EBMT risk score of 0, 47% of 1 and 34% of 2. Median follow-up for patients alive was 87 months (range 2-144 months). Data were obtained from 72 teams in 26 countries as listed in the Appendix. Survival was analyzed by the Kaplan-Meier method, using SPSS (version 22, Armonk, NY, USA). The Gray test was used to compare cumulative incidences of nonrelapse mortality and relapse as competing risks using R package 'cmprsk'. 8 At the time of the analysis, 164 patients (85%) were alive and 29 (15%) had died. The probability of survival at 5 years was 85% (Figure 1) . In more detail, 86% were alive for risk score 0, 90% for risk score 1 and 77% for risk score 2. The cumulative incidence of death without relapse was 12% and the cumulative incidence of relapse was 19% at 50 months, respectively (Figure 2 ).
This study shows the results that can be obtained today with allogeneic HSCT using standard myeloablative conditioning, standard GvHD prophylaxis and an optimal stem cell source when the transplant is performed in CP with a low-EBMT risk score. Transplant-related mortality was low. These results are even more remarkable as they were obtained from a large number of teams all over Europe. Based on the previously published longterm data, it can be expected that the probability of survival of these patients at 20 years will exceed 75% and 490% of these long-term survivors will be free of their disease. 9 These data should not alter the current algorithms concerning first-or second-line therapy. 2 However, they will be essential to define risk-adapted strategies for patients with suboptimal or failed response to TKIs. If such patients have an HLA-identical sibling donor and a low risk for transplant-related mortality as defined by an EBMT risk score of 0-2, they may preferentially be referred for HSCT. In contrast, if no such donor is available or if the risk score exceeds two, HSCT might be deferred and third generation TKI treatment may be the better option. 
